UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Expert opinion on drug metabolism & toxicology, 2020-11, Vol.16 (11), p.1063-1078

2020

Volltextzugriff (PDF)

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Frontiers in immunology, 2020-12, Vol.11, p.599417-599417

2020

Volltextzugriff (PDF)

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Journal of psychopharmacology (Oxford), 2020-03, Vol.34 (3), p.326-335

2020

Volltextzugriff (PDF)

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Current drug metabolism, 2021-01, Vol.22 (5), p.399-410

2021

Volltextzugriff (PDF)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Clinical and translational science, 2021-11, Vol.14 (6), p.2132-2138

2021

Volltextzugriff (PDF)

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Drugs in R&D, 2024-03, Vol.24 (1), p.97-108

2024

Volltextzugriff (PDF)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Scientific reports, 2022-11, Vol.12 (1), p.19067-7, Article 19067

2022

Volltextzugriff (PDF)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm

Frontiers in pharmacology, 2021-02, Vol.11, p.628956

2021

Volltextzugriff (PDF)

Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects

Biomedicine & pharmacotherapy, 2021-01, Vol.133, p.110955, Article 110955

2021

Volltextzugriff (PDF)

Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive

International journal of molecular sciences, 2022-11, Vol.23 (23), p.14986

2022

Volltextzugriff (PDF)

Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects

European journal of clinical pharmacology, 2020-03, Vol.76 (3), p.431-437

2020

Volltextzugriff (PDF)

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

European journal of clinical pharmacology, 2008-01, Vol.64 (1), p.43-50

2008

Volltextzugriff (PDF)

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Journal of dermatological science, 2018-02, Vol.89 (2), p.136-145

2018

Volltextzugriff (PDF)

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

International journal of molecular sciences, 2019-07, Vol.20 (13), p.3232

2019

Volltextzugriff (PDF)

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

Journal of pharmacokinetics and pharmacodynamics, 2021-04, Vol.48 (2), p.213-224

2021

Volltextzugriff (PDF)

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

European journal of clinical pharmacology, 2017-02, Vol.73 (2), p.151-156

2017

Volltextzugriff (PDF)

Integrated pharmacokinetics and pharmacodynamics in drug development

Clinical pharmacokinetics, 2007-01, Vol.46 (9), p.713-737

2007

Volltextzugriff (PDF)

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Scientific reports, 2020-03, Vol.10 (1), p.4410, Article 4410

2020

Volltextzugriff (PDF)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

CPT: pharmacometrics and systems pharmacology, 2023-01, Vol.12 (1), p.74-86

2023

Volltextzugriff (PDF)

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Nature medicine, 2007-02, Vol.13 (2), p.150-155

2007

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

CPT: pharmacometrics and systems pharmacology, 2021-07, Vol.10 (7), p.735-747

2021

Volltextzugriff (PDF)

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

Clinical pharmacokinetics, 2017-12, Vol.56 (12), p.1499-1511

2017

Volltextzugriff (PDF)

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239

Clinical and translational science, 2024-07, Vol.17 (7), p.e13883-n/a

2024

Volltextzugriff (PDF)

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans

Biomedicine & pharmacotherapy, 2021-12, Vol.144, p.112363, Article 112363

2021

Volltextzugriff (PDF)

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Pharmacology, 2014-01, Vol.94 (3-4), p.148-156

2014

Volltextzugriff (PDF)

1 – 25 von 339

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(330)
Mit Volltextzugriff
(258)

Publikationsform

Artikel
(336)
Tagungsberichte
(3)

Sprache

Englisch
(339)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm

Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects

Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive

Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

Integrated pharmacokinetics and pharmacodynamics in drug development

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Suchergebnisse filtern